Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: CAG Gastroenterology/Nutrition

University of Manitoba

$30,000.00

Establishing the morbidity and mortality of ERCP: A population-based study.

EF 2009-10

Résumé
Endoscopic retrograde cholangiopancreatography (ERCP), is an procedure widely performed in Canada since the early 1980's as a "low risk" procedure to diagnose and treat illnesses of the bile ducts and pancreas including: common bile duct stones , bile duct infections, biliary and pancreatic cancers, and pancreatitis (pancreas inflammation). Although it is generally more safe then traditional surgical or procedures, ERCP is associated with significant risks including acute pancreatitis, infection, perforation and even death. The incidence of these complications has been estimated at 10%, 1%, 0.1%, and 0.05% respectively. The only data published to date have been from large volume, tertiary care centers with a high level of expertise, which may lead to underestimated risks and overestimated benefits of ERCP. This study plans to examine the "real-world" risks and benefits associated with ERCP by establishing a population based database including all patients who have undergone ERCP in the province of Manitoba since 1984. We can achieve this in Manitoba because all residents of the province have unique personal health identification numbers through which their longterm medical histories can be tracked using the province's administrative health databases. We will explore the rates of complications such as pancreatitis, cholangitis, perforation, and hospitalization, and also of mortality. We will create an age, sex, and location matched group who have never had ERCP as well as a second control group who have had cholecystectomy without ERCP to serve as disease control group. We will compare incidence ratios for hospitalization, and mortality between the ERCP cohort and the non-ERCP control group and the non-ERCP/cholecystectomy cohort. Finally, we will establish trends in ERCP morbidity and mortality between 1984 and 2009. Ours will be the most comprehensive exploration of ERCP undertaken in Canada and will have generalizability for elsewhere in the world.
Programme
Operating Grant: CAG Gastroenterology/Nutrition
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
193182
Name
Bernstein Charles N
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
CIHR - INMD - CAG (Canadian Association of Gastroenterology) Partnership
Projecttitle
Establishing the morbidity and mortality of ERCP: A population-based study.
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$30,000
Cihrequipment2
$0
Programname2
Operating Grant: CAG Gastroenterology/Nutrition
Keyworddelim
Biliary Disease; Endoscopic Retrograde Cholangiopancreatography (Ercp); Endoscopy; Morbidity And Mortality; Pancreatic Disease
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP), is an procedure widely performed in Canada since the early 1980's as a "low risk" procedure to diagnose and treat illnesses of the bile ducts and pancreas including: common bile duct stones , bile duct infections, biliary and pancreatic cancers, and pancreatitis (pancreas inflammation). Although it is generally more safe then traditional surgical or procedures, ERCP is associated with significant risks including acute pancreatitis, infection, perforation and even death. The incidence of these complications has been estimated at 10%, 1%, 0.1%, and 0.05% respectively. The only data published to date have been from large volume, tertiary care centers with a high level of expertise, which may lead to underestimated risks and overestimated benefits of ERCP. This study plans to examine the "real-world" risks and benefits associated with ERCP by establishing a population based database including all patients who have undergone ERCP in the province of Manitoba since 1984. We can achieve this in Manitoba because all residents of the province have unique personal health identification numbers through which their longterm medical histories can be tracked using the province's administrative health databases. We will explore the rates of complications such as pancreatitis, cholangitis, perforation, and hospitalization, and also of mortality. We will create an age, sex, and location matched group who have never had ERCP as well as a second control group who have had cholecystectomy without ERCP to serve as disease control group. We will compare incidence ratios for hospitalization, and mortality between the ERCP cohort and the non-ERCP control group and the non-ERCP/cholecystectomy cohort. Finally, we will establish trends in ERCP morbidity and mortality between 1984 and 2009. Ours will be the most comprehensive exploration of ERCP undertaken in Canada and will have generalizability for elsewhere in the world.
Competitiondate
200910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Bernstein, Charles N; Moffatt, Dana C
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $15,000~ $0~Inst of Nutr Metabolism &Diab~ $15,000~ $0~